JUNE – SEPTEMBER 2026 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
AIFA July 21 Tovorafenib – LGG BRAF. The Italian Medicines Agency (AIFA) has authorised the marketing of the Type II RAF kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade-glioma (LGG) harbouring a BRAF fusion or […]